UBS reiterates Quidel stock rating at Neutral on weak Q1 results

QuidelOrtho preannounced disappointing first-quarter results, citing weaker respiratory sales, slower China distributor sales from reimbursement headwinds, and conflict-related disruption in the Middle East. UBS kept a Neutral rating and $17 price target, while noting management still sees the low end of fiscal 2026 guidance as achievable and expects positive free cash flow. The stock trades at $12.01, below UBS's target and near its 52-week low, with the earnings call scheduled for May 5.

Analysis

QDEL is signaling a classic post-hype reset: the immediate loser is the company itself, but the second-order winner is anyone competing for hospital and lab budget share in immunoassay and molecular testing. When management is forced to defend the low end of long-dated guidance while near-term demand is already slipping, distributors tend to de-stock before they re-order, which can extend the revenue air pocket beyond the quarter that first broke. That creates a setup where the next leg is less about one weak print and more about a multi-quarter normalization in channel confidence.

The key risk is that this is not just respiratory seasonality; China reimbursement friction and delayed EMEA orders suggest timing and procurement behavior are deteriorating simultaneously. If the company’s mix stays pressured, margin recovery may lag revenue recovery by 1-2 quarters because fixed-cost absorption worsens when volumes fall in a business with meaningful manufacturing leverage. The market is likely still pricing this like a temporary guide-down, but the real hazard is a ratcheting down of consensus for 2026 as investors update the implied run-rate.

The contrarian view is that the selloff may already be discounting a lot of bad news if free cash flow stays positive and the company can credibly defend outer-year guidance. That matters because balance-sheet stress is often what turns a tactical miss into a structural short, and this still looks more like an earnings-quality problem than an imminent solvency issue. If the upcoming call avoids further cuts and management quantifies a recovery path in China and respiratory, the stock could stage a sharp relief rally simply because positioning is likely de-risked into the event.

Key Decisions for Investors

• Short QDEL into the May 5 earnings call or buy near-dated puts; the setup favors a 1-2 week catalyst trade where downside can extend if management reframes the issue as structural rather than transitory.
• Use a downside put spread in QDEL rather than naked puts to capture another leg lower while limiting premium burn if management holds guidance; best risk/reward is likely the first 10-15% move after the call.
• Pair trade: short QDEL / long a diversified diagnostics or tools name with more stable end markets, to isolate company-specific demand/channel risk from broader healthcare beta.
• If QDEL rebounds on no-new-news commentary, fade strength unless management explicitly restores confidence in China and EMEA order timing; the stock is vulnerable to air-pocket rallies that fail on lower volume.
• For longer-horizon investors, wait for revised consensus and channel checks before buying; the better entry is after the market has fully priced 2026 estimates down, not on headline FCF stability alone.